Search results for: 'Detection of Polluting Carbonaceous Particles biological samples'

This study provides data for the Russian in vitro diagnostics (IVD) market. Hematology, hemostasis (coagulation), urinalysis, microbiology, clinical chemistry, point of care testing, molecular diagnostics, immunochemistry, and others namely, tissue diagnostics and self-monitoring blood glucose, are the segments discussed in this market. Market reve...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

Healthcare expenditure in Singapore is expected to grow, fueled by factors such as rising incomes and a progressively aging population. Diagnostics has emerged as a way for earlier and better identification of diseases to control rising healthcare costs in Singapore. Hence, the country has become a natural choice for many global diagnostic companie...

China is one of the fastest growing healthcare markets in the world. Traditionally, healthcare services have been dominated by the public sector; however, 2014 onward, the trend reversed with greater private sector participation. China still faces a number of challenges: unequal distribution of healthcare resources across the country; lack of an ef...

The study covers the healthcare market which develops and provides products, solutions, and/or services across the care spectrum for diagnosis, treatment, and prevention. The biosimilars market in India is expected to cross $0.9 billion by 2020. The growing prevalence of chronic diseases with an increasing aged population in India and globally, c...